A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT06121843
Trial Phases:	Phase I	Protocol IDs:	CA088-1005 (primary) NCI-2024-00171
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT06121843

Summary

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in
combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed
and/or refractory multiple myeloma (RRMM).

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.